Navigation Links
MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
Date:1/30/2008

ings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as a going concern, (2) increase Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.


'/>"/>
SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Sagent Pharmaceuticals, Inc. to Present at Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
2. Access Pharmaceuticals Announces $2.7 Million New Equity
3. Ferring Pharmaceuticals Announces EUFLEXXA(TM) as Title Sponsor of the National Senior Games Hockey Championships and the GeezerJock of the Year Award
4. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
5. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
6. Onyx Pharmaceuticals to Present at Wachovia Healthcare Conference
7. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
8. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
9. VIA Pharmaceuticals Names Rebecca Taub Senior Vice President of Research and Development
10. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
11. Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... FierceBiotech today announced its annual “Fierce ... of 2014. FierceBiotech editors John Carroll and Damian ... winners. Those selected are identified as some of ... , "It's always a lot of fun ... companies," said Carroll. "This year in particular you'll find ...
(Date:9/22/2014)... BETHESDA, Md. , Sept. 22, 2014  Spherix Incorporated ... fostering and monetization of intellectual property, today announced that the ... patent to the Company in the month of September that ... The issued patent is: USRE45,121 , ... 2014 , Filing date: Dec 27, 2012 ...
(Date:9/20/2014)... 2014 HealthTronics, Inc. , ... radiology products and services, has signed a distribution ... Clinicon Corporation for its high precision laser ... minimally invasive, mobile, surgical technology—offering more choices for ... agreement, HealthTronics will make available Clinicon’s FDA-cleared SureLase™ ...
(Date:9/19/2014)... to move data would consume much less power ... as chips, transistor counts rise. , Of the ... emitters, modulators, and detectors emitters are the ... optical chips is molybdenum disulfide (MoS2), which has ... atom-thick layer. Other experimental on-chip light emitters have ...
Breaking Biology Technology:FierceBiotech Announces Annual “Fierce 15” Winners of 2014 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 2Spherix Notified by United States Patent & Trademark Office of New Standard Essential Patent Issued to Spherix 3HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 2HealthTronics Announces Distribution Agreement with Clinicon-Laser Surgical Device Expands Minimally Invasive, Mobile Technology Portfolio 3Toward optical chips 2Toward optical chips 3
... Leader in, Animal Health and Strengthens Product Pipeline, Adding ... ... Projects, KENILWORTH, N.J., Nov. 19 Schering-Plough,Corporation (NYSE: ... BioSciences N.V., creating a stronger combined,company with broader human and animal ...
... discovery of a new way to manipulate light a million ... Science this week. , Using a special hollow-core photonic ... has opened the door to what could prove to be ... and trapping. , The team, led by Dr Fetah Benabid, ...
... The Committee for,Medicinal Products for Human Use ... (EMEA), granted Abbott (NYSE: ABT ) a ... treatment,of moderate to severe plaque psoriasis. Psoriasis will ... is a non-contagious, chronic autoimmune disease that causes,the ...
Cached Biology Technology:Schering-Plough Completes Acquisition of Organon BioSciences 2Schering-Plough Completes Acquisition of Organon BioSciences 3Schering-Plough Completes Acquisition of Organon BioSciences 4Schering-Plough Completes Acquisition of Organon BioSciences 5Discovery of a new way to manipulate light a million times more efficiently 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 2Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 3Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 4Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 5Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 6Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 7Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis 8
(Date:9/22/2014)... Sept. 22, 2014 NXT-ID, Inc. (NASDAQ: ... the growing mobile commerce market, issues the following corporate ... recent funding. Letter from the ... round of funding and joined the NASDAQ to support ... its other biometric and authentication products and services. This strategic ...
(Date:9/21/2014)... 22, 2014The story of cowpea (black-eyed peas) is a ... biggest problemseven more fascinating is the story of the ... Cowpea: The Food Legume of the 21st Century to ... and use. The book was recently published by the ... Institute of Tropical Agriculture (IITA). , Singh has devoted ...
(Date:9/21/2014)... was previously thought, newborn immune T cells may have ... according to a new study led by King,s College ... that of adults, babies may still be able to ... in the journal Nature Medicine . , Our ... of immune cells, including neutrophils which play an important ...
Breaking Biology News(10 mins):NXT-ID Issues Shareholder Corporate Update 2NXT-ID Issues Shareholder Corporate Update 3NXT-ID Issues Shareholder Corporate Update 4Immune system of newborn babies is stronger than previously thought 2
... Smithsonian,s Barro Colorado Island research station in Panama, organized ... Science, Policy & Management at the University of California, ... since the first census 33 years ago. Long ... and a group of stalwart volunteers, each armed with ...
... for Marine Sciences at the University of Gothenburg have discovered ... Gullmarsfjord north of Gothenburg. The bacterium has been named ... center. Researcher Matthias Obst from the Department of ... Sven Lovn Centre for Marine Sciences, a new institute owned ...
... and calcium supplements appear to reduce the risk of breast ... Cancer Research 101st Annual Meeting 2010. "It is ... and your breast cancer risk is reduced tomorrow," said Jaime ... Puerto Rico. "However, we did see a long-term effect in ...
Cached Biology News:A howling success: The fifth howler monkey census on Barro Colorado Island 2
Human Cell Line Slides...
Mouse monoclonal [3576] to Yellow Fever Virus ( Abpromise for all tested applications). Antigen: Tissue / cell preparation...
... 2 Detection System combines the indirect ... principle and Signets unique formulation of ... and reliablility. Signet reagents will achieve ... and automated protocols. ,Signets USA ...
6X Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Biology Products: